MS4A1 and B-cell non-Hodgkin lymphoma: Recently, MS4A1 has also been detected in other cancer tissues, including glioblastoma, mucinous colorectal adenocarcinoma, lymphomas, esophageal cancer, ovarian cancer, glioma, and lung adenocarcinoma, indicating that the therapeutic application of Rituximab may extend beyond B-cell lymphomas (97).